

## Department Meeting at NUH

Date	Aug 25 <sup>th</sup>
Time	18:00 – 19:00 Hrs SGT
Venue	Seminar Rooms T07-03/04, Level 7, NUHS Tower Block
Audience	~30 [Senior Consultants, Consultants, Fellows]
Format	Physical (F2F)   Snacks will be served (Bento Boxes)
Guest Speaker	<p><b>Prof Glenn Yiu, USA</b></p> <p>Dr. Glenn Yiu is an Associate Professor of Ophthalmology at UC Davis. He earned his dual MD-PhD degrees at Harvard Medical School, residency training at the Massachusetts Eye &amp; Ear Infirmary, and vitreoretinal fellowship at Duke. He joined UC Davis as a clinician-scientist and vitreoretinal surgeon in 2014, where he now leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases. His focuses include ocular imaging technologies, gene editing and delivery, and animal models of retinal disease. He reported the first use of CRISPR-based genome editing as a treatment strategy for wet AMD, discovered the use of microneedles for suprachoroidal viral injections for gene delivery, and pioneered important studies on drusen evolution in rhesus monkeys. He also employs ocular imaging technologies to develop an optically-triggered animal model of geographic atrophy, and study vascular roles in retinal diseases. He currently serves as Director of the UC Davis Reading Center and Director of Tele-ophthalmology, where he has pioneered a tele-retinal screening program to expand eye screening among diabetic patients in Northern California.</p> <p>Dr. Yiu has published numerous peer-reviewed scientific articles and book chapters, and is the editor of the textbook "Vitreoretinal Disorders." He also serves on the editorial board of Scientific Reports, as a member of the ARVO Annual Meeting Program Committee, and as a course lecturer at the American Academy of Ophthalmology. He has received numerous awards including the Ronald G. Michels Fellowship, the Heed Fellowship, the Retina Society Fellowship Research Award, and the Macula Society Evangelos S. Gragoudas Award. He is also supported by the National Eye Institute, the BrightFocus Foundation, the E Matilda Ziegler Foundation, the ARVO Foundation, Lions Club International Foundation, the Alcon Research Institute, the CITRIS/Banatao Institute, and the Macula Society. In 2016, he was named as one of 21 "Emerging Vision Scientists" by the National Alliance for Eye and Vision Research for his cutting-edge research.</p>

## OBJECTIVES

- To inform the department about Roche's entry in Ophthalmology and Vabysmo
- To highlight the current treatment burden / unmet need for retinal diseases (e.g. gap between clinical trial and real-world outcomes, a patient survey on injection anxiety and desire for longer-acting treatment, % population of suboptimal response to anti-VEGF)
- To explain the scientific & research advancement in identifying Ang/Tie as a new disease pathway
- To provide a high-level overview of faricimab's clinical programme, outcomes (non-inferior visual acuity, durability, comparable safety) and ability to address current unmet needs

## AGENDA

Time	Agenda (Tentative)	Presenter
18:00 – 18:10 10 mins	Introduction	Caroline C., NUH
18:10 – 18:40 <b>30 mins</b>	Presenting a Novel Approach to Treating Retinal Diseases <ul style="list-style-type: none"> <li>• Current retinal diseases treatment burden and unmet needs</li> <li>• The role of the Ang/Tie pathway in retinal diseases</li> <li>• Faricimab's clinical programme overview, incl. Phase 3 trial outcomes in nAMD and DME</li> <li>• 1 real-world faricimab patient case sharing from the US</li> </ul>	Glenn Y., USA
18:40 – 18:55 15 mins	Q&A Session	Glenn Y., USA
18:55 – 19:00 05 mins	Closing Remarks	Caroline C., NUH